Clinical Trial Update: Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating fenretinide for geographic atrophy in dry age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• Fenretinide (fenretinide)

Snippet

Sponsor: Sirion Therapeutics, Inc. | Conditions: Geographic Atrophy, Dry Age Related Macular Degeneration | Phase 2 | Status: COMPLETED